Literature DB >> 2383089

Treatment of polymyalgia rheumatica and giant cell arteritis.

M T Watts, M E Nelson, I G Rennie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2383089      PMCID： PMC1004157          DOI： 10.1136/ard.49.7.568-c

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

Authors:  V Kyle; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

2.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

3.  Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.

Authors:  P A Reilly; P J Maddison
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

4.  Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors.

Authors:  M Beri; M R Klugman; J A Kohler; S S Hayreh
Journal:  Ophthalmology       Date:  1987-08       Impact factor: 12.079

5.  Prognosis in giant-cell arteritis.

Authors:  E Graham; A Holland; A Avery; R W Russell
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.